Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease
Phase 3
Recruiting
- Conditions
- Diabetic NephropathiesKidney Failure, ChronicDiabetes Mellitus Type 1Heart Failure
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-01-22
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- Alessandro Doria
- Target Recruit Count
- 150
- Registration Number
- NCT06217302
- Locations
- ๐บ๐ธ
Stanford University Medical Center, Stanford, California, United States
๐บ๐ธBarbara Davis Center / University of Colorado Denver, Aurora, Colorado, United States
๐บ๐ธNorthwestern University Feinberg School of Medicine, Chicago, Illinois, United States
A Pilot Study of Fenofibrate to Prevent Kidney Function Loss in Type 1 Diabetes
Phase 2
Active, not recruiting
- Conditions
- Diabetic Nephropathies
- Interventions
- Other: Placebo
- First Posted Date
- 2021-06-18
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Alessandro Doria
- Target Recruit Count
- 40
- Registration Number
- NCT04929379
- Locations
- ๐บ๐ธ
Joslin Diabetes Center, Boston, Massachusetts, United States
๐บ๐ธLahey Hospital and Medical center, Burlington, Massachusetts, United States
๐บ๐ธBrehm Center for Diabetes Research / University of Michigan, Ann Arbor, Michigan, United States
A Multicenter Clinical Trial of Allopurinol to Prevent Kidney Function Loss in Type 1 Diabetes
Phase 3
Completed
- Conditions
- Coronary Artery DiseaseDiabetic Nephropathies
- Interventions
- Drug: Placebo
- First Posted Date
- 2013-12-20
- Last Posted Date
- 2020-12-04
- Lead Sponsor
- Alessandro Doria
- Target Recruit Count
- 530
- Registration Number
- NCT02017171
- Locations
- ๐จ๐ฆ
Mount Sinai Hospital / University of Toronto, Toronto, Ontario, Canada
๐บ๐ธEmory University - Grady Memorial Hospital, Atlanta, Georgia, United States
๐บ๐ธJacobi Medical Center, Bronx, New York, United States
ยฉ Copyright 2025. All Rights Reserved by MedPath